Cyxone (DB:4CX) - Stock Price, News & Analysis

4CX Stock Overview

A clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. More details

4CX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 10.8% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (SEK4M)

Does not have a meaningful market cap (€11M)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the German market

Cyxone AB (publ) Competitors

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

co.don

XTRA:CNW

€6.5m

Paion

DB:PA8K

€45.7k

Price History & Performance

Summary of all time highs, changes and price drops for Cyxone
Historical stock prices
Current Share Price	SEK 0.0002
52 Week High	SEK 0.03
52 Week Low	SEK 0.0001
Beta	0.42
11 Month Change	-94.12%
3 Month Change	-94.12%
1 Year Change	-97.80%
33 Year Change	-99.95%
5 Year Change	-99.95%
Change since IPO	-99.96%

Recent updates

Shareholder Returns

	4CX	DE Biotechs	DE Market
7D	-83.3%	0.8%	-1.3%
1Y	-97.8%	-17.5%	7.4%

Return vs Industry: 4CX underperformed the German Biotechs industry which returned -16.7% over the past year.

Return vs Market: 4CX underperformed the German Market which returned 7.1% over the past year.

Price Volatility

Is 4CX's price volatile compared to industry and market?
4CX volatility
4CX Average Weekly Movement	1,448.7%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4CX's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4CX's weekly volatility has decreased from 5450% to 1449% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2015	3	Kjell Stenberg	www.cyxone.com

Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.

Cyxone AB (publ) Fundamentals Summary

How do Cyxone's earnings and revenue compare to its market cap?
4CX fundamental statistics
Market cap	€954.28k
Earnings (TTM)	-€1.91m
Revenue (TTM)	€303.43k

3.1x

P/S Ratio

-0.5x

P/E Ratio

Is 4CX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4CX income statement (TTM)
Revenue	SEK 3.52m
Cost of Revenue	SEK 0
Gross Profit	SEK 3.52m
Other Expenses	SEK 25.68m
Earnings	-SEK 22.16m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 29, 2024

Earnings per share (EPS)	-0.059
Gross Margin	100.00%
Net Profit Margin	-629.96%
Debt/Equity Ratio	0%

How did 4CX perform over the long term?

See historical performance and comparison

4CX Stock Overview

Rewards

Risk Analysis

Cyxone AB (publ) Competitors

HMSE:SBH

€419.8k

BST:BPXA

€772.4k

XTRA:CNW

€6.5m

DB:PA8K

€45.7k

Price History & Performance

Recent News & Updates

Cyxone AB (publ) to Report Q3, 2024 Results on Nov 29, 2024

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.045 loss in 2Q 2023)

Cyxone AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.297851 million.

Cyxone AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 23.03211 million.

Cyxone AB (publ) Provides an Update on its Research and Development Program

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.062 loss in 1Q 2023)

Recent updates

Cyxone AB (publ) to Report Q3, 2024 Results on Nov 29, 2024

Second quarter 2024 earnings released: kr0.02 loss per share (vs kr0.045 loss in 2Q 2023)

Cyxone AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.297851 million.

Cyxone AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 23.03211 million.

Cyxone AB (publ) Provides an Update on its Research and Development Program

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.062 loss in 1Q 2023)

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: €0.48

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: €0.49

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: €0.50

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - €0.71

Shareholder Returns

Price Volatility